Top-Rated StocksTop-RatedNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis → Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (From InvestorPlace) (Ad) Free ROIV Stock Alerts $11.23 -0.18 (-1.58%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$10.91▼$11.4550-Day Range$9.87▼$11.7452-Week Range$8.24▼$13.24Volume3.95 million shsAverage Volume3.83 million shsMarket Capitalization$9.05 billionP/E Ratio2.16Dividend YieldN/APrice Target$16.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Roivant Sciences alerts: Email Address Roivant Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside50.5% Upside$16.90 Price TargetShort InterestBearish8.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.36) to ($1.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.43 out of 5 starsMedical Sector489th out of 921 stocksPharmaceutical Preparations Industry223rd out of 421 stocks 3.5 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoivant Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Roivant Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.27% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Roivant Sciences has recently increased by 1.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 2.2 News and Social Media Coverage News SentimentRoivant Sciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search InterestOnly 7 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to grow in the coming year, from ($1.36) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is 2.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is 2.16, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 154.01.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe CHIPS Act MotherlodeIf you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this.Click here to see my #1 investment for 2024. About Roivant Sciences Stock (NASDAQ:ROIV)Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Stock News HeadlinesMay 16 at 4:05 PM | globenewswire.comRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024May 7, 2024 | investorplace.comBiotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareMay 1, 2024 | investorplace.com3 Healthcare Stocks With the Potential to Triple Your Investment by 2026April 25, 2024 | businesswire.comRoivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisApril 24, 2024 | seekingalpha.comRoivant Sciences: Cashing In On Vants And VenturesApril 14, 2024 | markets.businessinsider.comSunrun (RUN) Gets a Buy from RBC CapitalApril 4, 2024 | msn.comRoivant's anti-inflammatory drug shows promise in mid-stage studyApril 2, 2024 | msn.comRoivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease StudyApril 2, 2024 | reuters.comRoivant's anti-inflammatory drug succeeds in mid-stage studyApril 2, 2024 | globenewswire.comRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionApril 1, 2024 | msn.comCompare with CoinDesk Market Index (CDICMI)March 26, 2024 | msn.comViking Therapeutics gains on early data for oral weight loss therapyMarch 26, 2024 | msn.com'Some people have principles': Internet divided as Vivek Ramaswamy predicts NY ruling against Trump could energize key voter groupMarch 14, 2024 | fr.investing.comL'objectif de cours de Roivant Sciences relevé à 16$ par Goldman SachsMarch 13, 2024 | edition.cnn.comTravere Therapeutics, Inc.March 13, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)February 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Roivant Sciences: Undervaluation and Promising Pipeline Drive Positive OutlookFebruary 15, 2024 | finance.yahoo.comDo You Think the Management of Roivant Sciences (ROIV) Can Create Value?February 14, 2024 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call TranscriptFebruary 14, 2024 | markets.businessinsider.comHold Rating on Roivant Sciences Amidst Mixed Performance and Strategic FocusFebruary 14, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Roivant SciencesFebruary 14, 2024 | finance.yahoo.comRoivant Sciences Third Quarter 2024 Earnings: Beats ExpectationsFebruary 14, 2024 | markets.businessinsider.comBuy Rating for Roivant Sciences: Solid Sales and Promising Clinical DevelopmentsFebruary 14, 2024 | realmoney.thestreet.comRoivant Sciences price target lowered by $2 at Goldman Sachs, here's whyFebruary 14, 2024 | finance.yahoo.comQ3 2024 Roivant Sciences Ltd Earnings CallSee More Headlines Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today5/19/2024Next Earnings (Confirmed)5/30/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees904Year FoundedN/APrice Target and Rating Average Stock Price Target$16.90 High Stock Price Target$23.00 Low Stock Price Target$12.00 Potential Upside/Downside+50.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.20 Trailing P/E Ratio2.16 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,009,030,000.00 Net Margins3,624.14% Pretax Margin3,461.24% Return on Equity-33.38% Return on Assets-26.06% Debt Debt-to-Equity Ratio0.06 Current Ratio27.79 Quick Ratio27.79 Sales & Book Value Annual Sales$61.28 million Price / Sales147.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book5.32Miscellaneous Outstanding Shares805,850,000Free Float768,777,000Market Cap$9.05 billion OptionableOptionable Beta1.30 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Matthew Gline (Age 40)CEO & Director Comp: $1.77MDr. Eric Venker M.D. (Age 37)Pharm.D., President & COO Comp: $1.28MDr. Mayukh Sukhatme M.D. (Age 48)President, Chief Investment Officer & Director Comp: $1.72MMr. Richard Pulik (Age 45)Chief Financial Officer Ms. Rakhi Kumar (Age 44)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Jo ChenGeneral CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 56)Head of Global Transactions & Risk Management Mr. Alex GasnerExecutive Vice President of Roivant HealthMore ExecutivesKey CompetitorsElanco Animal HealthNYSE:ELANCatalentNYSE:CTLTLegend BiotechNASDAQ:LEGNViking TherapeuticsNASDAQ:VKTXCerevel TherapeuticsNASDAQ:CEREView All CompetitorsInsiders & InstitutionsWhitefort Capital Management LPBought 800,000 shares on 5/17/2024Ownership: 0.297%Ikarian Capital LLCSold 51,212 shares on 5/17/2024Ownership: 0.012%California State Teachers Retirement SystemSold 16,089 shares on 5/16/2024Ownership: 0.036%Ionic Capital Management LLCBought 50,000 shares on 5/16/2024Ownership: 0.006%Kennedy Capital Management LLCBought 26,196 shares on 5/16/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions ROIV Stock Analysis - Frequently Asked Questions Should I buy or sell Roivant Sciences stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks. What is Roivant Sciences' stock price target for 2024? 10 brokers have issued 1 year price targets for Roivant Sciences' stock. Their ROIV share price targets range from $12.00 to $23.00. On average, they anticipate the company's share price to reach $16.90 in the next year. This suggests a possible upside of 50.5% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts. How have ROIV shares performed in 2024? Roivant Sciences' stock was trading at $11.23 at the beginning of the year. Since then, ROIV shares have increased by 0.0% and is now trading at $11.23. View the best growth stocks for 2024 here. When is Roivant Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 30th 2024. View our ROIV earnings forecast. How can I listen to Roivant Sciences' earnings call? Roivant Sciences will be holding an earnings conference call on Thursday, May 30th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) posted its earnings results on Monday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.10. The firm had revenue of $21.60 million for the quarter, compared to analysts' expectations of $24.49 million. Roivant Sciences had a net margin of 3,624.14% and a negative trailing twelve-month return on equity of 33.38%. The firm's revenue was up 402.3% compared to the same quarter last year. During the same period last year, the business posted ($0.48) EPS. What ETFs hold Roivant Sciences' stock? ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), First Trust Health Care AlphaDEX Fund (FXH), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), Global X Guru Index ETF (GURU), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Biotechnology ETF (IBBQ) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). Who are Roivant Sciences' major shareholders? Roivant Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Patient Square Capital LP (1.52%), Vanguard Group Inc. (1.01%), Baker BROS. Advisors LP (0.92%), Whitefort Capital Management LP (0.30%), Penn Davis Mcfarland Inc. (0.20%) and Tyro Capital Management LLC (0.19%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ROIV) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.